Study Finds Migraine Device CefalyŽ an Effective Treatment for Refractory Migraine

Monday, June 12, 2017 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 12, 2017 /PRNewswire/ -- A new clinical trial reveals that CefalyŽ, the first FDA-approved external trigeminal

nerve stimulation device for the prevention of frequent episodic migraines, has been used successfully on migraine patients who do not respond to usual oral migraine medication (refractory migraine).

The results, published in BMC Neurology,

an international peer-reviewed publication, showed that the CefalyŽ treatment reduced significantly the headache days and the acute anti-migraine medication intake in migraine patients that didn't previously respond to usual preventive oral migraine medications. Two out of three patients (66%) said they were satisfied by the treatment.

"We're excited to offer migraineurs hope and solution when usual oral preventive medication does not work. This is a great step that confirms CefalyŽ efficacy, particularly when medication fails, which is among the most difficult demographic of patients to treat," said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology, and a member of the team that invented the device.

Migraine affects 38 million people in the U.S., according to the Migraine Research Foundation. The debilitating neurological condition impacts all aspects of a migraineur's life. Almost a third of the patients suffered more than three migraines a month and needed a migraine preventive treatment in order to reduce the frequency of the attacks. The study results confirm the high efficacy of CefalyŽ, even when other treatments didn't work. The constant accumulation of clinical data about the CefalyŽ shows clearly that CefalyŽ, offers the best safety efficacy ratio and thus is becoming the first line treatment for patients having frequently migraine attacks.    

CefalyŽ, is a palm-sized, prescription-only, device that works through a self-adhesive electrode that's placed on the forehead and a magnetic connection, which sends tiny electrical impulses through the skin to the upper branches of the trigeminal nerve to desensitize the trigeminovascular system. The device, which is not yet covered by most insurance companies, costs $349 and comes with a 60-day money back guarantee. CefalyŽ is indicated for those ages 18 and older. Women who are pregnant or could become pregnant should check with their doctor before using CefalyŽ.

About CEFALYŽ TechnologyCEFALYŽ Technology is a Belgium-based company, with US offices based in Wilton, Connecticut, specializing in electronics for medical applications. It has developed external cranial stimulation technology for applications in the field of neurology; in particular for treating migraines. For more information, visit http://www.Cefaly.us. Find Cefaly on Twitter: @Cefaly, Facebook: http://www.facebook.com/CefalyEN, and YouTube: http://www.youtube.com/c/CEFALYTechnology. 

Media Contact: Maria Coder 646-494-4773 m.coder@cefaly.us

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-finds-migraine-device-cefaly-an-effective-treatment-for-refractory-migraine-300472076.html

SOURCE CEFALY Technology



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook